BCAX
Bicara Therapeutics Inc. Common StockBCAX
BCAX
About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
66.82% more ownership
Funds ownership: 0% [Q2] → 66.82% (+66.82%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
99%
upside
Avg. target
$41
135%
upside
High target
$47
167%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target | 139%upside $42 | Buy Initiated | 6 Dec 2024 |
Stifel Stephen Willey 44% 1-year accuracy 7 / 16 met price target | 167%upside $47 | Buy Initiated | 8 Oct 2024 |
Morgan Stanley Judah Frommer 38% 1-year accuracy 3 / 8 met price target | 99%upside $35 | Overweight Initiated | 8 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
Neutral
GlobeNewsWire
1 month ago
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET.
Neutral
24/7 Wall Street
2 months ago
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
Neutral
GlobeNewsWire
3 months ago
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Bicara Therapeutics' shares began trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” All of the shares of common stock were sold by Bicara Therapeutics.
Positive
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.
Positive
Reuters
3 months ago
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut
Shares of Bicara Therapeutics surged nearly 46% in their market debut on Friday, signaling strong investor interest for the TPG-backed cancer therapy developer.
Neutral
GlobeNewsWire
3 months ago
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics' shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Bicara Therapeutics.
Positive
Reuters
3 months ago
Bicara Therapeutics targets $265 mln proceeds in upsized US IPO
Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans to raise up to $265 million through an upsized initial public offering (IPO) in the United States.
Neutral
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, including three names that filed to raise $100 million or more. Two biotechs are scheduled to complete IPOs next Thursday, each aiming to raise $200 million.
Positive
Reuters
3 months ago
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO
Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the markets.
Charts implemented using Lightweight Charts™